Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) issued its earnings results on Thursday. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32), Zacks reports. During the same quarter in the previous year, the firm posted ($1.00) earnings per share.
Eledon Pharmaceuticals Trading Up 2.0 %
Shares of ELDN stock opened at $3.51 on Friday. The stock has a 50 day moving average of $4.17 and a 200 day moving average of $3.86. The stock has a market cap of $209.68 million, a P/E ratio of -1.75 and a beta of 0.80. Eledon Pharmaceuticals has a twelve month low of $1.52 and a twelve month high of $5.54.
Analyst Upgrades and Downgrades
Separately, Guggenheim initiated coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 target price on the stock.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Articles
- Five stocks we like better than Eledon Pharmaceuticals
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- What is the Nasdaq? Complete Overview with History
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Stock Average Calculator
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
